E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

Jarle Bruun; Peter W. Eide; Christian Holst Bergsland; Oscar Bruck; Aud Svindland; Mariliina Arjama; Katja Välimäki; Merete Bjornslett; Marianne G. Guren; Olli Kallioniemi; Arild Nesbakken; Ragnhild A. Lothe; Teijo Pellinen

doi:10.1002/1878-0261.13159

E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

Jarle Bruun, Peter W. Eide, Christian Holst Bergsland, Oscar Bruck, Aud Svindland, Mariliina Arjama, Katja Välimäki, Merete Bjornslett, Marianne G. Guren, Olli Kallioniemi, Arild Nesbakken, Ragnhild A. Lothe, Teijo Pellinen

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Tidskrift	Molecular oncology
Volym	16
Nummer	12
Sidor (från-till)	2312-2329
Antal sidor	18
ISSN	1574-7891
DOI	https://doi.org/10.1002/1878-0261.13159
Status	Publicerad - 2022
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.1002/1878-0261.13159

Molecular Oncology - 2021 - Bruun - E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression isSlutlig publicerad version, 3,71 MBLicens: CC BY

Citera det här

Bruun, J., Eide, P. W., Bergsland, C. H., Bruck, O., Svindland, A., Arjama, M., Välimäki, K., Bjornslett, M., Guren, M. G., Kallioniemi, O., Nesbakken, A., Lothe, R. A., & Pellinen, T. (2022). E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular oncology, 16(12), 2312-2329. https://doi.org/10.1002/1878-0261.13159

@article{0ba8ec3497ec4d5ebd23d49df39ff333,

title = "E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models",

keywords = "colorectal cancer, drug screening, E-cadherin, multiplex immunohistochemistry, pharmacoproteomics, prognostic biomarker, MESENCHYMAL TRANSITION, CELL-LINES, MOLECULAR SUBTYPES, RESISTANCE, GEFITINIB, PHENOTYPE, CARCINOMA, MARKER, EGFR, EMT, 3122 Cancers",

author = "Jarle Bruun and Eide, {Peter W.} and Bergsland, {Christian Holst} and Oscar Bruck and Aud Svindland and Mariliina Arjama and Katja V{\"a}lim{\"a}ki and Merete Bjornslett and Guren, {Marianne G.} and Olli Kallioniemi and Arild Nesbakken and Lothe, {Ragnhild A.} and Teijo Pellinen",

year = "2022",

doi = "10.1002/1878-0261.13159",

language = "English",

volume = "16",

pages = "2312--2329",

journal = "Molecular oncology",

issn = "1574-7891",

publisher = "Wiley",

number = "12",

}

Bruun, J, Eide, PW, Bergsland, CH, Bruck, O, Svindland, A, Arjama, M , Välimäki, K, Bjornslett, M, Guren, MG, Kallioniemi, O, Nesbakken, A, Lothe, RA & Pellinen, T 2022, 'E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models', Molecular oncology, vol. 16, nr. 12, s. 2312-2329. https://doi.org/10.1002/1878-0261.13159

E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. / Bruun, Jarle; Eide, Peter W.; Bergsland, Christian Holst et al.
I: Molecular oncology, Vol. 16, Nr. 12, 2022, s. 2312-2329.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

TY - JOUR

T1 - E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

AU - Bruun, Jarle

AU - Eide, Peter W.

AU - Bergsland, Christian Holst

AU - Bruck, Oscar

AU - Svindland, Aud

AU - Arjama, Mariliina

AU - Välimäki, Katja

AU - Bjornslett, Merete

AU - Guren, Marianne G.

AU - Kallioniemi, Olli

AU - Nesbakken, Arild

AU - Lothe, Ragnhild A.

AU - Pellinen, Teijo

PY - 2022

Y1 - 2022

KW - colorectal cancer

KW - drug screening

KW - E-cadherin

KW - multiplex immunohistochemistry

KW - pharmacoproteomics

KW - prognostic biomarker

KW - MESENCHYMAL TRANSITION

KW - CELL-LINES

KW - MOLECULAR SUBTYPES

KW - RESISTANCE

KW - GEFITINIB

KW - PHENOTYPE

KW - CARCINOMA

KW - MARKER

KW - EGFR

KW - EMT

KW - 3122 Cancers

U2 - 10.1002/1878-0261.13159

DO - 10.1002/1878-0261.13159

M3 - Article

SN - 1574-7891

VL - 16

SP - 2312

EP - 2329

JO - Molecular oncology

JF - Molecular oncology

IS - 12

ER -